The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Update on TRANSFORM: liso-cel vs SOC in R/R LBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, outlines the findings of the prespecified interim analysis of TRANSFORM, a Phase III trial comparing the efficacy and safety of lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy versus standard of care (SOC) treatment with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) (NCT03575351). Dr Kamdar explains that the study met its primary endpoint of event-free survival (EFS), with a median EFS of 10.1 months in the liso-cel arm vs 2.3 months in the SOC arm. In addition, patients treated with liso-cel experienced statistically significant improvements in complete response (CR) rate and progression-free survival (PFS), with a trend in overall survival (OS) favouring liso-cel. The safety profile of liso-cel was manageable, with no grade 4 or 5 cytokine release syndrome (CRS) or neurological adverse events. This data suggests liso-cel as a potential new SOC for patients with R/R LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Research Support/Funding: TG Therapeutics, Genentech, Novartis Consultancy: AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene Speaker’s bureau: SeaGen DMC: Celgene, Genentech
